SEC Form 4 · accession 0001209191-16-124037
PUMA BIOTECHNOLOGY, INC. · PBYI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven Lo
Officer — Chief Commercial Officer
Period of report
May 25, 2016
Accepted (ET)
May 27, 2016 · 4:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001401667
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| STOCK OPTION (RIGHT TO BUY)F1 | $35.61 | May 25, 2016 | A | 30,000 | A | — | May 24, 2026 | COMMON STOCK | 30,000 | 30,000 | D |
Explanation of responses
- F1The vesting commencement date ("Vesting Commencement Date") of the option is May 25, 2016. The option vests (i) with respect to one-third (1/3) of the shares underlying the option on the first anniversary of the Vesting Commencement Date and (ii) with respect to 1/36th of the shares underlying the option, on each monthly anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person's continued service with the Issuer; provided, however, that if the Reporting Person experiences a Qualifying Termination (as defined in the letter agreement between the Issuer and the Reporting Person) on or within eighteen (18) months following a Change in Control (as defined in the Issuer's 2011 Incentive Award Plan), then the option shall vest and become exercisable upon the effectiveness of the Release (as defined in the letter agreement).